- In March 2023, Pfizer announced a Phase 2 trial for its anti-inflammatory agent aimed at reducing cerebral edema post-hematoma.
- In July 2022, Roche collaborated with a European neurology institute to co-develop biomarkers for drug responsiveness in intracranial hematoma patients.
- In 2024, South Korea’s health authority approved a novel neuroprotective formulation for acute hematoma management in emergency care units.
- The report also highlights emerging trends such as biomarker-driven drug targeting, AI in neuroimaging-based treatment stratification, and integration of neurorehabilitation with pharmacologic therapy.
Frequently Asked Questions
Growing interest in neuroprotective formulations, development of blood-brain barrier-penetrating drugs, and integration of AI for rapid diagnosis are key trends.
Key drivers include rising TBI incidence, improved emergency response systems, and drug development focused on reducing secondary brain injury.
Challenges include limited drugs with high efficacy, complex clinical trial pathways, and lack of awareness in low-income regions.
The Subdural Hematoma segment dominates due to its high occurrence rate and greater focus in clinical research and intervention protocols
